NewEdge Advisors LLC Boosts Holdings in Hims & Hers Health, Inc. (NYSE:HIMS)

NewEdge Advisors LLC lifted its position in Hims & Hers Health, Inc. (NYSE:HIMS - Free Report) by 83.4% in the fourth quarter, according to its most recent Form 13F filing with the SEC. The firm owned 20,021 shares of the company's stock after purchasing an additional 9,105 shares during the period. NewEdge Advisors LLC's holdings in Hims & Hers Health were worth $484,000 at the end of the most recent quarter.

Other institutional investors also recently bought and sold shares of the company. SlateStone Wealth LLC lifted its holdings in Hims & Hers Health by 4.0% during the fourth quarter. SlateStone Wealth LLC now owns 10,640 shares of the company's stock worth $257,000 after buying an additional 413 shares during the period. Blume Capital Management Inc. lifted its stake in shares of Hims & Hers Health by 100.0% during the 4th quarter. Blume Capital Management Inc. now owns 1,200 shares of the company's stock worth $29,000 after purchasing an additional 600 shares during the last quarter. Summit Investment Advisors Inc. boosted its position in Hims & Hers Health by 3.3% during the fourth quarter. Summit Investment Advisors Inc. now owns 19,853 shares of the company's stock valued at $480,000 after purchasing an additional 628 shares in the last quarter. Harbour Investments Inc. boosted its position in Hims & Hers Health by 18.8% during the fourth quarter. Harbour Investments Inc. now owns 5,269 shares of the company's stock valued at $127,000 after purchasing an additional 833 shares in the last quarter. Finally, Stonekeep Investments LLC grew its stake in Hims & Hers Health by 5.5% in the fourth quarter. Stonekeep Investments LLC now owns 16,952 shares of the company's stock valued at $410,000 after purchasing an additional 882 shares during the last quarter. 63.52% of the stock is currently owned by hedge funds and other institutional investors.

Insider Buying and Selling

In other Hims & Hers Health news, insider Soleil Boughton sold 4,153 shares of the business's stock in a transaction on Monday, February 3rd. The shares were sold at an average price of $35.30, for a total value of $146,600.90. Following the completion of the transaction, the insider now owns 161,497 shares in the company, valued at $5,700,844.10. The trade was a 2.51 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, CEO Andrew Dudum sold 128,127 shares of the business's stock in a transaction on Tuesday, February 18th. The stock was sold at an average price of $58.27, for a total value of $7,465,960.29. Following the transaction, the chief executive officer now directly owns 97,687 shares of the company's stock, valued at $5,692,221.49. The trade was a 56.74 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 666,234 shares of company stock worth $26,387,645. Insiders own 17.71% of the company's stock.

Hims & Hers Health Stock Up 11.9 %

Shares of HIMS traded up $4.32 during mid-day trading on Friday, reaching $40.48. The company had a trading volume of 41,134,283 shares, compared to its average volume of 16,713,244. The stock has a market capitalization of $8.99 billion, a P/E ratio of 92.26 and a beta of 1.65. The stock has a 50 day moving average of $32.19 and a two-hundred day moving average of $31.30. Hims & Hers Health, Inc. has a 52-week low of $11.20 and a 52-week high of $72.98.

Hims & Hers Health (NYSE:HIMS - Get Free Report) last announced its quarterly earnings data on Monday, February 24th. The company reported $0.11 earnings per share for the quarter, beating analysts' consensus estimates of $0.09 by $0.02. Hims & Hers Health had a return on equity of 10.97% and a net margin of 8.19%. The company had revenue of $481.14 million for the quarter, compared to analyst estimates of $494.56 million. On average, sell-side analysts expect that Hims & Hers Health, Inc. will post 0.29 earnings per share for the current year.

Analyst Upgrades and Downgrades

HIMS has been the topic of a number of recent analyst reports. Needham & Company LLC raised their price target on shares of Hims & Hers Health from $31.00 to $61.00 and gave the company a "buy" rating in a report on Tuesday, February 25th. Citigroup decreased their price objective on Hims & Hers Health from $27.00 to $25.00 and set a "sell" rating for the company in a report on Friday, April 25th. Piper Sandler boosted their target price on Hims & Hers Health from $24.00 to $35.00 and gave the stock a "neutral" rating in a research note on Tuesday, February 25th. Bank of America upped their target price on Hims & Hers Health from $22.00 to $26.00 and gave the company an "underperform" rating in a research report on Tuesday. Finally, Morgan Stanley lowered their price target on Hims & Hers Health from $60.00 to $40.00 and set an "equal weight" rating for the company in a report on Tuesday. Two analysts have rated the stock with a sell rating, eight have issued a hold rating and three have issued a buy rating to the stock. According to data from MarketBeat, the stock has an average rating of "Hold" and a consensus target price of $36.92.

Hims & Hers Health Profile

Hims & Hers Health, Inc operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.